Summary. The 
INTRODUCTION
The antifertility activities in rats and mice of a number of the 1,1,2-triarylalk-1-enes and 1,1,2-triarylalkan-l-ols with basic ether groups have been reported by Harper & Walpole (1966) , Emmens (1971a, b) , Collins, Hobbs & Emmens (1971) and Emmens & Carr (1973) . These series of compounds have some members which are very highly potent, particularly as postcoital antifertility agents, and which have some interesting properties as precoital antifertility agents. They vary in oestrogenic and antioestrogenic properties, and in the influence of isomerism on these and on their antifertility activities. Those most active as antifertility agents tend to have atypical, flat dose-response curves as oestrogens, but in general they exhibit much less oestrogenicity than could be expected to account for their antifertility potencies. Few have any marked degree of antioestrogenicity by conventional tests.
The chemical synthesis of fourteen 1,1,2-triarylalk-l-enes and ten 1,1,2-triarylalkan-l-ols was reported by Collins et al. (1971) (Emmens, 1969) , the low slopes and 'impeded'-type activity of many of these compounds make bioassay difficult and the ED50 estimates presented are sometimes quite imprecise. Thus, with the rat, trans-\l could only be as¬ signed an ED50 within the limits 0-2 to 5-0 mg (Table 3) Emmens (1969) .
In all tests, groups often were standard and several dose levels of each com¬ pound were used. Injection was in 0-05 or 0-1 ml peanut oil/dose, oral ad¬ ministration in 0-05 or 0-1 ml of 25 to 50% aqueous propylene glycol.
The compounds investigated are listed in Table 1 With 4i, given in a single oral dose of 100 µg, pregnancy was terminated in all mice dosed on any day between Days 1 and 4, inclusive, but was maintained in 4/9, 3/9 and 6/10 mice dosed on Days 5, 6 and 7, respectively, and in 6/9 controls. When given by injection, the compound was as active and pregnancy was maintained in 0/10 or 1/10 mice injected on Days 1 to 5, inclusive, and in 2/9 and 4/10 injected on Days 6 and 7, respectively. In the controls, the com¬ parable figure was 6/10. In both cases, control values were lower than usual. With 4j at a dose of 10 /tg/day orally, single doses gave 1,2,1,5,7,9 and 6 pregnancies in groups of 10 dosed on Days 1 to 7 as before (controls-8/10). All (Emmens, 1965a) . Where a comparison was made, no compound showed significantly higher subcutaneous than oral potency as an antifertility agent. This was not true of oestrogenic activity, although the same tendency was seen. Emmens (1965a) found that the daily dose of a typical oestrogen required on Days 1 to 3 or 4 to 6 in the mouse to reduce fertility to 50% of controls is approximately the oestro-genie ED50 in vaginal smear tests. It is very different with most of these com¬ pounds, which do, however, vary considerably. Thus, cis-Al and 3h are not much different from typical oestrogens, whereas trans-\l, 4h and 4j show oestrogenic/ antifertility ED50 ratios of around 250:1.
Results with the rat are shown in Table 3 . They are rather sparse and were The antifertility potency of some of these compounds is perhaps up to five or ten times that of any so far reported elsewhere except for frank oestrogens. Gopalchari, Iyer, Kamboj & Kar (1970 have tested some other very potent compounds which, however, would not seem to be as active as 4h or 4j, although comparisons between results from different sources are difficult to make with any degree of confidence.
